| Naslov: | Mechanism of action, potency and efficacy : considerations for cell therapies |
|---|
| Avtorji: | ID Simon Jr., Carl G. (Avtor)
ID Bozenhardt, Erich H. (Avtor)
ID Celluzzi, Christina M. (Avtor)
ID Dobnik, David (Avtor)
ID Grant, Melanie L. (Avtor)
ID Lakshmipathy, Uma (Avtor)
ID Nebel, Thiana (Avtor) |
|---|
| Datoteke: |  URL - Izvorni URL, za dostop obiščite https://doi.org/10.1186/s12967-024-05179-7
 PDF - Predstavitvena datoteka, prenos (4,26 MB)
MD5: 98DD6E0119EEFC3B0509163C71948613
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: |  NIB - Nacionalni inštitut za biologijo
|
|---|
| Povzetek: | One of the most challenging aspects of developing advanced cell therapy products (CTPs) is defining the mechanism of action (MOA), potency and efficacy of the product. This perspective examines these concepts and presents helpful ways to think about them through the lens of metrology. A logical framework for thinking about MOA, potency and efficacy is presented that is consistent with the existing regulatory guidelines, but also accommodates what has been learned from the 27 US FDA-approved CTPs. Available information regarding MOA, potency and efficacy for the 27 FDA-approved CTPs is reviewed to provide background and perspective. Potency process and efficacy process charts are introduced to clarify and illustrate the relationships between six key concepts: MOA, potency, potency test, efficacy, efficacy endpoint and efficacy endpoint test. Careful consideration of the meaning of these terms makes it easier to discuss the challenges of correlating potency test results with clinical outcomes and to understand how the relationships between the concepts can be misunderstood during development and clinical trials. Examples of how a product can be “potent but not efficacious” or “not potent but efficacious” are presented. Two example applications of the framework compare how MOA is assessed in cell cultures, animal models and human clinical trials and reveals the challenge of establishing MOA in humans. Lastly, important considerations for the development of potency tests for a CTP are discussed. These perspectives can help product developers set appropriate expectations for understanding a product’s MOA and potency, avoid unrealistic assumptions and improve communication among team members during the development of CTPs. |
|---|
| Ključne besede: | cell therapy product, efficacy endpoint test, mechanism of action, potency test, metrology |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Datum objave: | 02.05.2024 |
|---|
| Leto izida: | 2024 |
|---|
| Št. strani: | str. [1]-17 |
|---|
| Številčenje: | Vol. 22, art. no. ǂ416 |
|---|
| PID: | 20.500.12556/DiRROS-19009  |
|---|
| UDK: | 576 |
|---|
| ISSN pri članku: | 1479-5876 |
|---|
| DOI: | 10.1186/s12967-024-05179-7 |
|---|
| COBISS.SI-ID: | 196774659 |
|---|
| Opomba: | Soavtorji: Erich H. Bozenhardt, Christina M. Celluzzi, David Dobnik, Melanie L. Grant, Uma Lakshmipathy, Thiana Nebel, Linda Peltier, Anthony Ratcliffe, James L. Sherley, Glyn N. Stacey, Rouzbeh R. Taghizadeh, Eddie H. P. Tan & Sandrine Vessillier;
Nasl. z nasl. zaslona;
Opis vira z dne 27. 5. 2024;
|
|---|
| Datum objave v DiRROS: | 27.05.2024 |
|---|
| Število ogledov: | 117 |
|---|
| Število prenosov: | 113 |
|---|
| Metapodatki: |     |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
